Lee Ainslie’s CARGO Therapeutics CRGX Stock Holding History

Lee Ainslie’s Portfolio CRGX Stock Details CRGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-400,000	Closed	-$9.26M	–	439
2023 Q4	$9.26M	Buy	+400,000	New	+$6.78M	0.19%	54

Other funds holding CRGX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Lee Ainslie's CRGX Position: Q1 2024 in Review

Lee Ainslie sold out of CARGO Therapeutics (CRGX) in Q1 2024, closing a stake of 400,000 shares — an estimated $9.26M sold.

Lee Ainslie first reported a position in CRGX in Q4 2023 and held it in 1 quarter. The position peaked at $9.26M in Q4 2023. 65 funds tracked by Wall St. Rank hold CRGX as of Q1 2024.

Lee Ainslie reported no remaining CARGO Therapeutics position as of Q1 2024 after selling out during the quarter.
Lee Ainslie sold 400,000 CARGO Therapeutics shares in Q1 2024, an estimated $9.26M.
Lee Ainslie first reported a position in CARGO Therapeutics in Q4 2023 and held it in 1 quarter.
Lee Ainslie's CARGO Therapeutics position peaked at $9.26M in Q4 2023.
65 funds tracked by Wall St. Rank held CARGO Therapeutics as of Q1 2024.

Based on Maverick Capital's 13F filing for Q1 2024, filed 15 May 2024.